SHENZHEN, China and Los Angeles, California — June 19, 2026 — Shenzhen Oculgen Biomedical Technology Co., Ltd. (“Oculgen”) today announced that the first U.S. participant has been enrolled in the STAT...

SHENZHEN, China and Berkeley, Calif. — [May 26, 2026] — Shenzhen Oculgen Biomedical Technology Co., Ltd. ("Oculgen"), a clinical-stage biotechnology company developing biologics for retinal ...

Oculgen Launches U.S. Phase II/III STAT Study to Advance Treatment for Neovascular Age-Related Macular Degeneration (nAMD)First clinical sites initiated and ready to enroll participantsShenzhen, China...

Oculgen Launches U.S. Phase II/III STAT Study to Advance Treatment for Neovascular Age-Related Macular Degeneration (nAMD)First clinical sites initiated and ready to enroll participantsShenzhen, China...

Shenzhen Oculgen Biomedical Technology Co., Ltd (Oculgen) announces the planned global initiation of Phase II clinical trials for its novel bispecific antibody, OCUL101. OCUL101 is the world’s first d...

Shenzhen Oculgen Biomedical Technology Co., Ltd. (“Oculgen”) is pleased to announce the successful completion of its $18 million Series A financing round. This round was led by LongRiver Investments, ...